-
Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies
Camille Serrate, Damien Pouessel, Helene Gauthier, Christine le Maignan, Luis Teixeira & Stephane Culine
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies
Camille Serrate, Damien Pouessel, Helene Gauthier, Christine le Maignan, Luis Teixeira & Stephane Culine
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies
Camille Serrate, Damien Pouessel, Helene Gauthier, Christine le Maignan, Luis Teixeira & Stephane Culine
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies
Camille Serrate, Damien Pouessel, Helene Gauthier, Christine le Maignan, Luis Teixeira & Stephane Culine
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies
Camille Serrate, Damien Pouessel, Helene Gauthier, Christine le Maignan, Luis Teixeira & Stephane Culine
Review: Clinical Trail Outcomes: Clinical Investigation
-
Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies
Camille Serrate, Damien Pouessel, Helene Gauthier, Christine le Maignan, Luis Teixeira & Stephane Culine
Review: Clinical Trail Outcomes: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
What does the future hold for uveal melanoma, a historically untreatable disease?
Alexander N Shoushtari , Richard D Carvajal
Editorial: Clinical Investigation
-
Rethinking Phase II clinical trial design in heart failure
Kory J Lavine , Douglas L Mann
Clinical Trail Methodology: Clinical Investigation
-
Rethinking Phase II clinical trial design in heart failure
Kory J Lavine , Douglas L Mann
Clinical Trail Methodology: Clinical Investigation
-
Rethinking Phase II clinical trial design in heart failure
Kory J Lavine , Douglas L Mann
Clinical Trail Methodology: Clinical Investigation
-
Rethinking Phase II clinical trial design in heart failure
Kory J Lavine , Douglas L Mann
Clinical Trail Methodology: Clinical Investigation
-
Rethinking Phase II clinical trial design in heart failure
Kory J Lavine , Douglas L Mann
Clinical Trail Methodology: Clinical Investigation
-
Rethinking Phase II clinical trial design in heart failure
Kory J Lavine , Douglas L Mann
Clinical Trail Methodology: Clinical Investigation
-
Approaches to clinical trials of new anti-tuberculous drugs
Charles M Bark, Jennifer J Furin & John L Johnson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Approaches to clinical trials of new anti-tuberculous drugs
Charles M Bark, Jennifer J Furin & John L Johnson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Approaches to clinical trials of new anti-tuberculous drugs
Charles M Bark, Jennifer J Furin & John L Johnson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Approaches to clinical trials of new anti-tuberculous drugs
Charles M Bark, Jennifer J Furin & John L Johnson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Approaches to clinical trials of new anti-tuberculous drugs
Charles M Bark, Jennifer J Furin & John L Johnson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Approaches to clinical trials of new anti-tuberculous drugs
Charles M Bark, Jennifer J Furin & John L Johnson
Review: Clinical Trail Outcomes: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation
-
Parkinsons disease: will therapy move beyond dopaminergic medication?
Livia Dezsi,L Vecsei
Review Article: Clinical Investigation